Author

Sebastian Mandel

Goethe University FrankfurtORCID 0009-0003-8281-1498Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

Ana CorrioneroiD· 2 shared Andreas KrämeriD· 2 shared Benedict‐Tilman BergeriD· 2 shared Daniela S. KrauseiD· 2 shared Hayuningbudi Saraswati· 2 shared Lewis ElsoniD· 2 shared Martin P. SchwalmiD· 2 shared Patricia Alfonso· 2 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

Ana CorrioneroORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistryJournal of Medicinal ChemistryPeer-reviewedJul 2, 2025

Covalent targeting leads to the development of LIMK1 isoform-selective inhibitors

Sebastian Mandel, Thomas Hanke, Niall Prendiville…·Stefan Knapp

This study develops a covalent LIMK1 inhibitor that selectively targets a unique cysteine, enabling isoform-specific studies of LIMK1 function.

6 citations

experimental assaydrug response / drug discovery

𝕏 PostBluesky

BiochemistryACS Chemical BiologyPeer-reviewedApr 14, 2025

Repurposing of the RIPK1 selective benzooxazepin-4-one scaffold for the development of a type-III LIMK1/2 inhibitor

Sebastian Mandel, Thomas Hanke, Sebastian Mathea…·Stefan Knapp

The paper repurposes a benzoxazepinone scaffold originally designed for RIPK1 inhibition to develop a novel type-III LIMK1/2 inhibitor with high selectivity.

5 citations

experimental assaydrug response / drug discovery

𝕏 PostBluesky